Dasacent 50 mg (Tablet)
Unit Price: ৳ 200.00 (1 x 10: ৳ 2,000.00)
Strip Price: ৳ 2,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Dasatinib |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Title and Categories
- Dasacent
- Cancer Therapy Medication
Indications
- Treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
- Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
- Pediatric patients 1 year of age and older with Ph+ CML in chronic phase
- Newly diagnosed Ph+ ALL in combination with chemotherapy
Mode of Action
- Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ kinases
- Predicted binding to multiple conformations of the ABL kinase
- Active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
- Inhibition of CML and ALL cell lines overexpressing BCR-ABL
Absorption
- Maximum plasma concentrations observed between 0.5 and 6 hours following oral administration
- Food effect: high-fat meal increased mean AUC of Dasatinib by 14%
Distribution
- Apparent volume of distribution is 2505 (CV% 93%)
- Binding of Dasatinib to human plasma proteins in vitro was approximately 96%
Elimination
- Mean terminal half-life of Dasatinib is 3 to 5 hours
- Mean apparent oral clearance is 363.8 l/hr (CV% 81.3%)
- Metabolized primarily by CYP3A4
- Elimination primarily via feces
Metabolism
- CYP3A4 primary enzyme responsible for active metabolite formation
- FMO-3 and UGT enzymes involved in formation of metabolites
- Active metabolite exposure represents approximately 5% of AUC of Dasatinib
Excretion
- Primarily via feces
- 4% of administered radioactivity recovered in urine within 10 days
Dosage & Administration
- Adult Chronic Phase CML: 100 mg orally once daily
- Adult Accelerated/Blast Phase CML or Ph+ ALL: 140 mg orally once daily
- Pediatric Dosage based on body weight
- Tablets should not be crushed, cut, or chewed
- Can be taken with or without food
Interaction
- CYP3A4 Inhibitors may increase Dasacet concentrations
- CYP3A4 Inducers may decrease Dasacet concentrations
- Gastric Acid Reducing Agents may decrease Dasacet concentrations
Contraindications
- Known hypersensitivity to Dasatinib or any component of the formulation
Side Effects
- Myelosuppression
- Bleeding-related events
- Fluid retention
- Cardiovascular events
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
- Effects on growth and development in pediatric patients
Pregnancy & Lactation
- Can cause fetal harm when administered to pregnant women
- Breastfeeding not recommended during treatment
Precautions & Warnings
- Severe thrombocytopenia, neutropenia, and anemia
- Bleeding risk
- Fluid retention risk
- Cardiac dysfunction risk
- Pulmonary arterial hypertension risk
- QT prolongation risk
- Severe dermatologic reactions risk
- Tumor lysis syndrome risk
Overdose Effects
- Experienced severe myelosuppression and bleeding in isolated cases
- Patients should be monitored closely for myelosuppression and given appropriate supportive treatment
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store below 30°C in a dry place
- Protect from light
- Keep out of the reach of children